The autonomic nervous system is the crucial link between the brain and the cardiovascular system. It is the final common pathway by which central disturbances - whether initiated by exogenous psychological or physical stress, or endogenous biochemical or structural perturbation - are translated into alterations in cardiac, endocrine, and vascular function. There is compelling evidence that disordered autonomic engagement of the heart and vasculature contributes importantly to many forms of cardiovascular disease: arrhythmias, hypertension, syncope, stroke, myocardial infarction, and sudden death. The goal of this Program Project is to achieve better understanding of how the brain exerts control over the autonomic nervous system. The integrating of the grant is autonomic cardiovascular regulation and the means by which the autonomic nervous system controls effector tissues. The rationale of the Program Project is the tightly coordinated testing of hypotheses addressing autonomic modulation of cardiovascular function in health and disease. Component projects address central and peripheral autonomic mechanisms, employing both integrated and reductionist approaches. The roles of specific body constituents (insulin, hormones, adrenoreceptors), endogenous mediators (nitric oxide, water), and afferent (osmopressor response), efferent (obesity hypertension), and endocrine (hypoglycemia, exercise, and hyperglycemia) mechanisms are examined. The programmatic approach facilitates the bidirectional transfer of information between the laboratory and the clinic because it brings together investigators with a wide range of skills who have a track record of discovering new fundamental knowledge and applying it to the creation of practical improvements in human health. This Program Project should lead directly to improved therapy in cardiovascular disease.
The brain and nervous system control blood pressure and how the body handles sugar (glucose). The research we propose includes a team of scientists working together to find better ways to control autonomic regulation of glucose and blood pressure. With better ways to control blood pressure and blood sugar, we can improve we will be able to improve the health of many people with these diseases.
|Biaggioni, Italo; Calhoun, David A (2016) Sympathetic Activity, Hypertension, and The Importance of a Good Night's Sleep. Hypertension 68:1338-1339|
|Harder, RenÃ©; Malow, Beth A; Goodpaster, R Lucas et al. (2016) Heart rate variability during sleep in children with autism spectrum disorder. Clin Auton Res 26:423-432|
|Mar, Philip L; Nwazue, Victor; Black, Bonnie K et al. (2016) Valsalva Maneuver in Pulmonary Arterial Hypertension: Susceptibility to Syncope and Autonomic Dysfunction. Chest 149:1252-60|
|Shibao, Cyndya A; Celedonio, Jorge E; Ramirez, Claudia E et al. (2016) A Common CD36 Variant Influences Endothelial Function and Response to Treatment with Phosphodiesterase 5 Inhibition. J Clin Endocrinol Metab 101:2751-8|
|Adefurin, Abiodun; Darghosian, Leon; Okafor, Chimalum et al. (2016) Alpha2A adrenergic receptor genetic variation contributes to hyperglycemia after myocardial infarction. Int J Cardiol 215:482-6|
|Raj, Satish R (2016) Row, row, row your way to treating postural tachycardia syndrome. Heart Rhythm 13:951-2|
|Joy, Nino G; Perkins, Jennifer M; Mikeladze, Maia et al. (2016) Comparative effects of acute hypoglycemia and hyperglycemia on pro-atherothrombotic biomarkers and endothelial function in non-diabetic humans. J Diabetes Complications 30:1275-81|
|Lateef, Dalya M; Xiao, Cuiying; Brychta, Robert J et al. (2016) Bombesin-like receptor 3 regulates blood pressure and heart rate via a central sympathetic mechanism. Am J Physiol Heart Circ Physiol 310:H891-8|
|Harder, Rene; Diedrich, Andre; Whitfield, Jonathan S et al. (2016) Smart Multi-Frequency Bioelectrical Impedance Spectrometer for BIA and BIVA Applications. IEEE Trans Biomed Circuits Syst 10:912-9|
|Iwuchukwu, Otito F; Ramirez, Andrea H; Shi, Yaping et al. (2016) Genetic determinants of variability in warfarin response after the dose-titration phase. Pharmacogenet Genomics 26:510-516|
Showing the most recent 10 out of 300 publications